#LBDAwarenessMonth
LightNews LightNews
alzassociation.bsky.social
During #LBDAwarenessMonth, take a moment to learn the differences between Alzheimer’s and dementia with Lewy bodies. Read more here: bit.ly/4he1UbK.
What's the Difference between Alzheimer's and Dementia With Lewy Bodies (DLB)? Comparing Common Early-Stage Symptoms -Memory loss is more profound in Alzheimer's. -Movement symptoms, like tremors and rigidity, are more likely to be an important cause of disability in DLB. -Hallucinations and misidentifications of familiar people are significantly more frequent in early DLB. -A blood pressure drop on standing, dizziness, falls and urinary incontinence are much more common in DLB.
October 27, 2026 at 9:30 PM
abfbrain.bsky.social
Meet 2026 Next Gen. Researcher Esteban Luna, MD, PhD. He’s researching the gene MPEG1 to see if it could be a target for treating conditions including Parkinson’s and dementia with Lewy bodies. Funded with the @alzassociation.bsky.social. #LBDawarenessmonth buff.ly/UCg0B6t
Researcher Feature: Esteban Luna, MD, PhD. Dr. Luna is a 2026 Next Generation Researcher studying Lewy Body Dementia. He will explore if the decreased expression of the gene MPEG1 in the brain’s immune cells is associated with accumulations of the protein alpha-synuclein, which leads to conditions like LBD and Parkinson’s. If so, this could lead to new therapeutic approaches targeting MPEG1 to treat these conditions. This research is funded by the Alzheimer's Association and the American Brain Foundation.
October 14, 2026 at 7:45 PM
abfbrain.bsky.social
Meet 2026 Cure One, Cure Many Award and 2020 Next Gen. Grant recipient Lenora Higginbotham, MD. She is researching molecular signatures to diagnose Lewy Body Dementia. Funded w/ Alzheimer’s Association and Michael J. Fox Foundation. #LBDawarenessmonth buff.ly/pQpEe5w
Researcher spotlight: Lenora Higginbotham, MD, 2026 Cure One, Cure Many Lewy Body Dementia Award. Despite having the same diagnosis, individuals with Lewy body dementia (LBD) can differ from each other in terms of their symptoms and underlying biology. This diversity, at a molecular level, is referred to as disease heterogeneity. To develop accessible methods to diagnose LBD in living patients, researchers must first identify the key biological signatures that correspond to different molecular processes and disease traits. Dr. Higginbotham’s team will study LBD plasma samples using a method called proteomic analysis. This refers to a large-scale, comprehensive study of all the proteins in a cell. They will employ machine-learning approaches to help identify differences in protein measurements among the samples that correspond with how the disease presents itself clinically. This will help scientists better understand individual variability in LBD, and thereby help to improve precision in diagnosis, prediction, and treatment. We're grateful to everyone who has made this research possible. This $1 million award is funded in collaboration with the Alzheimer’s Association, the Michael J. Fox Foundation for Parkinson’s Research, and donors like you.
October 2, 2026 at 7:47 PM
adrcmass.bsky.social
October marks #LBDAwarenessMonth. Did you know that Lewy Body Dementia is the 2nd most common type of dementia after Alzheimer's disease? Learn more here: bit.ly/LBDflyer #WeAreMADRC
October 8, 2025 at 6:39 PM